Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Director

28 Jun 2012 07:00

RNS Number : 3062G
CareCapital Group plc
28 June 2012
 



28 June 2012

 

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

 

Appointment of Non-executive Director

 

CareCapital (AIM: CARE) is pleased to announce the appointment of Trevor Brown as a Non-executive Director with immediate effect.

 

Trevor Brown (66) has been a strategic investor in real estate and equities for more than 30 years. Mr Brown is a director of Free Association Books Limited in London.

 

He has a beneficial interest as at the date of this announcement in 15,334,001 ordinary shares of CareCapital, representing 9.38% of the Company's current issued share capital.

 

There is no further information required to be disclosed in relation to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.

 

Commenting on the appointment, Dr Mike Sinclair, CareCapital's CEO, said, "I am pleased that Trevor has agreed to join the Board as a Non-executive Director. He is, and has been, a supporter of our plans to refocus CareCapital on the provision of advanced cancer treatment services. His experience and track record will greatly benefit our Board, our management team and our shareholders. I welcome him to CareCapital."

 

For further information, please visit www.carecapital.co.uk or contact:

 

Michael Sinclair, CEO

 

Sandy Jamieson

Simon Hudson / Kelsey Traynor

CareCapital Group PlcLibertas Capital Corporate Finance Ltd

(NOMAD & Joint Broker)

Tavistock Communications

(Financial PR & IR)

 020 3617 8727

 

020 7569 9650

 

020 7920 3150

 

About CareCapital

CareCapital recently announced a restructuring to reflect its strategy to reposition the Company primarily as an investor in, and provider of, advanced cancer treatments. Current investments in medical centre development projects are to be transferred to the Company's wholly owned subsidiary - The Healthcare Property Company Limited - which will continue to progress existing schemes and expand through securing new medical centre projects in the UK. This company will also provide property related support services to the wider CareCapital group. The Company also announced that it will be seeking shareholder authority at the earliest opportunity to change its name to Advanced Oncotherapy plc.

 

CareCapital is building a portfolio of innovative cancer treatment services to capture opportunities in the cancer diagnosis and treatment market, building on its 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its newly launched Oncotherapy Resources business focused on early stage breast cancer treatment. Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK and which has secured planning approval for its first London based centre off Moorgate in the City of London, within easy access of a number of London's major hospitals.

 

CareCapital also specialises, as an innovative developer, in primary care real estate, particularly multi-occupancy premises that accommodate a variety of different, but often synergetic healthcare providers. This is particularly relevant at a time when the Government is intent on expanding primary care, bringing more services together under one roof and closer to patients in their own communities. Working in partnership with local authorities, projects can involve significant urban regeneration, with mixed-use and mixed-economy developments incorporating housing, healthcare, childcare, retail and other appropriate facilities for the community.

 

-ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABKODNABKDQAB
Date   Source Headline
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters
1st Mar 20232:05 pmRNSSecond Price Monitoring Extn
1st Mar 20232:00 pmRNSPrice Monitoring Extension
27th Jan 20234:53 pmEQSHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
18th Jan 20232:00 pmRNSOperational update
17th Jan 20233:10 pmEQSHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
30th Dec 20221:00 pmRNSTotal Voting Rights
30th Dec 20229:24 amRNSDirector/PDMR Shareholding
29th Dec 20223:12 pmRNSDirector/PDMR Shareholding
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 202212:40 pmRNSSecond Price Monitoring Extn
23rd Dec 202212:35 pmRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSEquity Subscription and Issue of Warrants
1st Dec 20227:00 amRNSIssue of Equity
28th Nov 20227:00 amRNSStudy showcases the potential superiority of LIGHT
3rd Nov 20223:20 pmRNSInvestor / Analyst Event Update
31st Oct 20225:00 pmRNSTotal Voting Rights
27th Oct 20227:31 amRNSPresentation highlights superiority of LIGHT
21st Oct 20227:00 amRNSNotice of Investor / Analyst Event
18th Oct 20227:00 amRNSEquity Subscription and Issue of Warrants
30th Sep 20225:00 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSInterim Results
29th Sep 20227:15 amEQSHardman & Co Research on Advanced Oncotherapy: Major milestone achieved
27th Sep 202210:30 amRNSLIGHT accelerator fully operational
31st Aug 20225:00 pmRNSTotal Voting Rights
23rd Aug 20223:09 pmRNSUpdate re admission of Subscription Shares
19th Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
17th Aug 20225:30 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
29th Jul 20224:30 pmRNSResult of AGM
7th Jul 202212:30 pmRNSHolding(s) in Company
30th Jun 20225:00 pmRNSTotal Voting Rights
30th Jun 20229:00 amRNSFinal results for the year ended 31 December 2021
28th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
13th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
31st May 20225:00 pmRNSTotal Voting Rights
27th May 202212:17 pmRNSHolding(s) in Company
11th May 20227:00 amRNSLIGHT system potential in delivering FLASH
29th Apr 20225:00 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNSVideo showcases progress on LIGHT system process
26th Apr 20227:00 amRNSOperational update
22nd Apr 20227:00 amRNSUpdate re admission of Subscription Shares
19th Apr 20224:05 pmRNSUpdate re admission of Subscription Shares
12th Apr 20227:13 amRNSEquity Subscription and Issue of Warrants
31st Mar 20225:00 pmRNSTotal Voting Rights
25th Mar 20229:30 amRNS£2m Subscription, Add'l Loan and Issue of Warrants
14th Mar 20227:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
4th Mar 20229:00 amRNSDirector/PDMR Notification
3rd Mar 20226:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.